2-Thioxo-4,5-tetramethylen-Δ⁴-oxazolin | 6670-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Thioxo-4,5-tetramethylen-Δ⁴-oxazolin
• 英文别名: 4,5,6,7-tetrahydro-3H-benzooxazole-2-thione；4,5,6,7-Tetrahydro-1,3-benzoxazol-2-thiol；4,5,6,7-tetrahydro-3H-1,3-benzoxazole-2-thione
• CAS: 6670-16-2
• 化学式: C₇H₉NOS
• 分子量: 155.221
• InChiKey: XMUDCLOLWTXZJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-Isothiocyanatocyclohexan-1-one 以 甲苯 为溶剂， 反应 10.0h， 生成 2-Thioxo-4,5-tetramethylen-Δ⁴-oxazolin
  参考文献：
  名称：

  Bobosik, Vladimir; Piklerova, Anna; Martvon, Augustin, Collection of Czechoslovak Chemical Communications, 1983, vol. 48, # 12, p. 3421 - 3425

  摘要：

  DOI：

文献信息

• ALKYLAMINOPYRIDINE DERIVATIVE
  申请人：Ando Makoto

  公开号：US20110015181A1

  公开（公告）日：2011-01-20

  The present invention relates to a compound that is useful for treatment of, for example, hypertension, arteriosclerosis, bulimia and obesity because of having an antagonistic action to a neuropeptide Y receptor and is represented by formula (I) [wherein R 1 represents hydrogen, cyano, or the like; R represents a group represented by formula (II); X 1 represents C 1-4 lower alkylene or the like; X 2 represents lower alkylene or the like; and Het represents a 5-membered heteroaromatic ring that has at least one nitrogen atom and, in addition, one or two hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms] or to a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，由式(I)表示，该化合物具有对神经肽Y受体的拮抗作用，因此可用于治疗高血压、动脉硬化、暴食症和肥胖症等疾病。其中，R1代表氢、氰或类似物；R代表由式(II)表示的基团；X1代表C1-4低烷基或类似物；X2代表低烷基或类似物；Het代表一个五元杂环芳香环，其中至少有一个氮原子，并且还有一个或两个来自氮、硫和氧原子组成的杂原子。该化合物或其药学上可接受的盐可用于治疗上述疾病。
• Spiroheptane salicylamides and related compounds as inhibitors of ROCK
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10829501B2

  公开（公告）日：2020-11-10

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• EP2264026
  申请人：——

  公开号：——

  公开（公告）日：——
• BOBOSIK, V.;PIKLEROVA, A.;MARTVON, A., COOLECT. CZECH. CHEM. COMMUN., 1983, 48, N 12, 3421-3425
  作者：BOBOSIK, V.、PIKLEROVA, A.、MARTVON, A.

  DOI：——

  日期：——
• SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20200131200A1

  公开（公告）日：2020-04-30

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.